CagriSema (cagrilintide + semaglutide)safety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for CagriSema (cagrilintide + semaglutide) as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. CagriSema (cagrilintide + semaglutide) is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

CagriSema's safety profile combines the class characteristics of GLP-1R agonism (gastrointestinal predominance) with the additional characteristics of amylin-receptor agonism. Phase II data showed the gastrointestinal adverse-event profile (nausea, vomiting) was broadly similar to semaglutide monotherapy at matched semaglutide dose, without meaningful worsening from the added cagrilintide component. This suggests that combination therapy does not multiply GI adverse events even though both components engage the appetite-suppressing pathway. Cagrilintide-specific adverse events include injection-site reactions (potentially slightly higher than semaglutide alone given the added component) and rare hypoglycaemia in insulin-treated diabetes contexts (amylin's insulin-adjacent pharmacology affects postprandial glucose profiles). Cardiovascular safety expectations parallel the semaglutide component's favourable cardiovascular profile as established in SELECT and related trials. The REDEFINE-3 cardiovascular-outcome trial will provide the definitive cardiovascular safety and benefit data for the combination. Theoretical concerns about additive central nervous system effects from combined amylin and GLP-1 receptor engagement have not surfaced clinically at Phase II magnitudes. The full Phase III programme will provide the larger and longer-duration safety dataset required for regulatory review. The FDA-mandated thyroid C-cell carcinoma class warning applies via the semaglutide component. Longer-term rare adverse events (acute pancreatitis, biliary disease, retinopathy) will be characterised through REDEFINE Phase III and eventual post-marketing surveillance.

UK regulatory status

CagriSema is **not** authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds **no marketing authorisation** in any jurisdiction as of 2026. The combination is in Phase III clinical development by Novo Nordisk through the REDEFINE programme; first regulatory filings are anticipated 2026-2028. Access is restricted to Phase III clinical-trial participation at selected UK NHS and private clinical-trial sites. Supply outside the clinical-trial framework is not legally available through MHRA-regulated channels. Both component peptides (cagrilintide and semaglutide) have some grey-market and research-chemical-market presence, particularly semaglutide given its licensed status and market prominence. Combined-product supply outside authorised channels is generally not the pattern — the components are more commonly seen individually. Supply for human use engages the Human Medicines Regulations 2012. CagriSema is not on the WADA Prohibited List (the GLP-1R class and amylin-family compounds are not currently prohibited). Not a controlled drug under the Misuse of Drugs Act 1971. For animal research under ASPA, both component peptides require standard project and personal licences.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. CagriSema (cagrilintide + semaglutide) is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full CagriSema (cagrilintide + semaglutide) research context including mechanism, study citations, and references, see the main CagriSema (cagrilintide + semaglutide) research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.